Spyre Therapeutics (SYRE) Equity Ratio: 2015-2025
Historic Equity Ratio for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to 0.90.
- Spyre Therapeutics' Equity Ratio rose 16.00% to 0.90 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.90, marking a year-over-year increase of 16.00%. This contributed to the annual value of 0.85 for FY2024, which is 58.09% up from last year.
- Per Spyre Therapeutics' latest filing, its Equity Ratio stood at 0.90 for Q3 2025, which was up 6.63% from 0.85 recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Equity Ratio ranged from a high of 0.90 in Q3 2025 and a low of -1.18 during Q3 2023.
- Its 3-year average for Equity Ratio is 0.41, with a median of 0.78 in 2024.
- In the last 5 years, Spyre Therapeutics' Equity Ratio plummeted by 260.48% in 2023 and then spiked by 200.83% in 2024.
- Spyre Therapeutics' Equity Ratio (Quarterly) stood at 0.76 in 2021, then fell by 7.40% to 0.71 in 2022, then fell by 23.87% to 0.54 in 2023, then soared by 58.09% to 0.85 in 2024, then climbed by 16.00% to 0.90 in 2025.
- Its Equity Ratio was 0.90 in Q3 2025, compared to 0.85 in Q2 2025 and 0.85 in Q1 2025.